Last reviewed · How we verify

Isotonic sodium chloride 0.9 percent

Rigshospitalet, Denmark · FDA-approved active Small molecule Under review

Isotonic sodium chloride 0.9 percent is a Crystalloid fluid / Electrolyte replacement solution Small molecule drug developed by Rigshospitalet, Denmark. It is currently FDA-approved for Fluid and electrolyte replacement in dehydration, Vehicle for intravenous drug administration, Maintenance of vascular access patency. Also known as: Isotonic saline.

Isotonic sodium chloride 0.9% restores and maintains fluid and electrolyte balance by providing a physiologically balanced saline solution that matches blood osmolarity.

Isotonic sodium chloride 0.9 percent is a small molecule modality used in various clinical trials for conditions such as Acute Kidney Injury, Skin Care, Postoperative Pain, Chronic Pain, and Analgesics. It is also known by synonyms including 0.9% NACL, 0.9% SALINE, and 0.9% SALINE SOLUTION.

At a glance

Generic nameIsotonic sodium chloride 0.9 percent
Also known asIsotonic saline
SponsorRigshospitalet, Denmark
Drug classCrystalloid fluid / Electrolyte replacement solution
ModalitySmall molecule
Therapeutic areaFluid and Electrolyte Management
PhaseFDA-approved

Mechanism of action

This solution contains sodium and chloride ions in concentrations (0.9% w/v) that are isotonic with human blood plasma, preventing osmotic shifts across cell membranes. It is used for fluid replacement, electrolyte supplementation, and as a vehicle for drug administration. The solution does not exert a pharmacological effect but rather serves as a physiological support agent.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Isotonic sodium chloride 0.9 percent

What is Isotonic sodium chloride 0.9 percent?

Isotonic sodium chloride 0.9 percent is a Crystalloid fluid / Electrolyte replacement solution drug developed by Rigshospitalet, Denmark, indicated for Fluid and electrolyte replacement in dehydration, Vehicle for intravenous drug administration, Maintenance of vascular access patency.

How does Isotonic sodium chloride 0.9 percent work?

Isotonic sodium chloride 0.9% restores and maintains fluid and electrolyte balance by providing a physiologically balanced saline solution that matches blood osmolarity.

What is Isotonic sodium chloride 0.9 percent used for?

Isotonic sodium chloride 0.9 percent is indicated for Fluid and electrolyte replacement in dehydration, Vehicle for intravenous drug administration, Maintenance of vascular access patency, Perioperative fluid management.

Who makes Isotonic sodium chloride 0.9 percent?

Isotonic sodium chloride 0.9 percent is developed and marketed by Rigshospitalet, Denmark (see full Rigshospitalet, Denmark pipeline at /company/rigshospitalet-denmark).

Is Isotonic sodium chloride 0.9 percent also known as anything else?

Isotonic sodium chloride 0.9 percent is also known as Isotonic saline.

What drug class is Isotonic sodium chloride 0.9 percent in?

Isotonic sodium chloride 0.9 percent belongs to the Crystalloid fluid / Electrolyte replacement solution class. See all Crystalloid fluid / Electrolyte replacement solution drugs at /class/crystalloid-fluid-electrolyte-replacement-solution.

What development phase is Isotonic sodium chloride 0.9 percent in?

Isotonic sodium chloride 0.9 percent is FDA-approved (marketed).

What are the side effects of Isotonic sodium chloride 0.9 percent?

Common side effects of Isotonic sodium chloride 0.9 percent include Hyperchloremic acidosis (with prolonged or excessive use), Fluid overload / Hypervolemia, Hypokalemia (with chronic use without potassium supplementation), Local phlebitis at infusion site.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing